Topics

Vaxil Bio licenses synthetic P-Esbp polymer from BGN Technologies

14:40 EST 13 Feb 2020 | Elsevier Business Intelligence

Israeli immunotherapy company Vaxil Bio Ltd. licensed a synthetic P-Esbp polymer from BGN Technologies, the tech transfer arm...

Original Article: Vaxil Bio licenses synthetic P-Esbp polymer from BGN Technologies

NEXT ARTICLE

More From BioPortfolio on "Vaxil Bio licenses synthetic P-Esbp polymer from BGN Technologies"

Quick Search

Relevant Topic

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...